Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program.
Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de
One of the most challenging decisions to make as you near retirement is when to claim Social Security benefits. Here are five reasons 65 might be the sweet spot.
Strong leasing demand and limited new supply are boosting top-tier office REITs like SL Green, BXP and Hudson Pacific, which trade far cheaper than data-center REITs Equinix and Digital Realty.
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.
Speaking at the 2026 TD Cowen Neuropsychiat
Every year, NFL teams spend months studying the next class of potential stars. My colleague Louis Navellier sees a similar dynamic unfolding in the stock market today. After years of mega-cap dominance, smaller companies are beginning to take the lead—but that doesn’t mean every small-cap stock deserves a place in your portfolio.
Palo Alto Networks and Fortinet shares are up 112% and 125% this year, respectively, as AI-driven demand for cybersecurity fuels strong earnings and technical breakouts for both stocks.
Huron Consulting Group (NASDAQ:HURN) expects continued double-digit growth through 2029 as healthcare providers, higher-education institutions and commercial clients navigate financial pressure, technology modernization and regulatory complexity, Chief Financial Officer John Kelly said during the Si
